# Arsanis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arsanis

- Industry: Pharmaceuticals
- Headquarters: Waltham, US
- Website: www.arsanis.com
- Total disclosed funding: $84M
- Latest round: Series D (Apr 24, 2017)
- Investors on record: 9

## About

Founded in 2010 and based in Massachusetts, United States, Arsanis, Inc. is a biopharmaceutical company that develops human monoclonal antibody therapeutics for the treatment of critical infectious diseases. In March 2019, X4 Pharmaceuticals merged with Arsanis, Inc. (Nasdaq: ASNS). In connection with the merger, Arsanis changed its name to X4 Pharmaceuticals, Inc. The combined organization commenced trading on March 14, 2019 on the Nasdaq Capital Market under the symbol XFOR.

## Funding rounds

- Series D, Apr 24, 2017, $46M — OrbiMed Advisors, Polaris Partners, EMBL Ventures, Alexandria Venture Investments, SV Health Investors, NeoMed, GV, Bill & Melinda Gates Foundation, Anna-Maria & Stephen Kellen Foundation
- Series C, Apr 12, 2016, $15M — SV Health Investors
- Series B, Jul 30, 2013, $13M — OrbiMed Advisors, Polaris Partners, SV Health Investors, NeoMed
- Series A, Feb 28, 2011, $10M — OrbiMed Advisors, Polaris Partners, SV Health Investors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series D
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series D
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B, Series C, Series D
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series B, Series D
- EMBL Ventures (https://capitalatlas.ai/funds/embl-ventures) — Series D
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series D
- GV (https://capitalatlas.ai/funds/gv) — Series D
- Bill & Melinda Gates Foundation — Series D
- Anna-Maria & Stephen Kellen Foundation — Series D